In large-animal parenteral manufacturing, cefquinome sulfate is not typically processed as a ready-to-use aqueous injection for long-term storage, because high-water-activity systems accelerate β-lactam ring hydrolysis and reduce syringe shelf life. A reference industrial concentration of 25 mg/mL cefquinome base activity is dispersed in an anhydrous oily vehicle, often ethyl oleate or fractionated medium-chain triglycerides gelled with aluminium stearate at 0.5–2.0% w/v. The vehicle is pre-sterilised by dry-heat at 160 °C for not less than 2 h or by filtration. The active is aseptically micronised under nitrogen. High-shear rotor-stator mixing at 8,000–12,000 rpm for 15–30 min at 15–25 °C disperses the solid phase; batch records should record torque increase as viscosity rises and a product-specific particle size D90 below 30 µm to prevent needle occlusion. The suspension is transferred by peristaltic pump to depyrogenated Type I or Type II glass vials under restricted access barrier systems. Terminal moist-heat sterilisation is avoided because of β-lactam thermolability. Process simulation media fills must achieve zero growth in three consecutive runs per Ph. Eur. 5.1.1. Release testing includes sterility per Ph. Eur. 2.6.1, bacterial endotoxins per Ph. Eur. 2.6.14, extractable volume, resuspendability after 25 °C/60% RH and 2–8 °C temperature cycling, and syringeability through a 16G needle. The terminal product is an injectable suspension for intramuscular administration to cattle and pigs for respiratory pathogens susceptible to cefquinome. Withdrawal periods must be aligned with current Annex entries in Commission Regulation (EU) No 37/2010 for the relevant milk and meat matrices.

Why Does the Uterine Infusion Vehicle Require Water-Free Composition and Controlled Low-Shear Viscosity?

Intrauterine cefquinome products are formulated for postpartum metritis and endometritis in dairy cows and are delivered through a flexible intrauterine catheter into a contaminated, low-pH environment containing purulent exudate and tissue debris. The vehicle must remain anhydrous or have water activity below 0.60 to prevent hydrolysis of the β-lactam ring during shelf storage and after partial dose exposure. A thickened non-aqueous base, typically based on white mineral oil or ethyl oleate with colloidal silica or aluminium stearate, is selected to retain active substance at the endometrial surface rather than draining through the cervical canal. Drug loading is adjusted to the approved dose after catheter placement; fill volumes commonly range from 10 mL to 30 mL, but the actual dose is dictated by the marketing authorisation. Manufacturing includes heat-sterilisation of the vehicle, aseptic addition of micronised cefquinome sulfate, and slow planetary mixing under vacuum to avoid entrapped air that would cause dose-weight variability in syringe filling. Viscosity is measured with a Brookfield viscometer at 25 °C and spindle speed 10 rpm; a product-specific target of 800–2,500 mPa·s is commonly used for syringeability and uterine retention, but it must be correlated to catheter expulsion force. The terminal product is a single-use uterine suspension filled into high-density polyethylene or polypropylene syringes or plastic vials with sealed luer catheter attachments. Compliance includes sterility per Ph. Eur. 2.6.1, endotoxins per Ph. Eur. 2.6.14, particulate control per Ph. Eur. 2.9.19, residual solvents per VICH GL18, and species-specific milk and meat withdrawal verification.

A lactating cow intramammary preparation containing cefquinome sulfate is a sterile, viscous, non-aqueous suspension filled into single-use polyethylene intramammary syringes with a cannula tip. A common reference composition provides 75 mg cefquinome base activity per 8 g syringe dispersed in mineral oil with a suspension stabiliser; the exact formula is product-specific. The manufacturing route involves pre-sterilisation of the oil base at 160–180 °C for 2 h, colloidal dispersion of the active under low-shear mixing, and filling under laminar airflow with in-line checkweighing. Because the target site is the lactating mammary gland, the suspension must be free of coarse particles larger than 25–50 µm to avoid streak-canal obstruction and to ensure uniform distribution in milk. Release testing includes particulate contamination per Ph. Eur. 2.9.19, sterility per Ph. Eur. 2.6.1, bacterial endotoxins per Ph. Eur. 2.6.14, and viscosity-time profile. Batch-to-batch particle settling is a recurring failure mode; resuspendability must be validated after 24 h, 7 days, and 30 days at 2–8 °C and 25 °C to ensure a uniform dose when the syringe is agitated before infusion. The terminal product is intended for intramammary infusion in dairy cattle with mastitis caused by susceptible organisms. Milk and meat withdrawal times must match current Commission Regulation (EU) No 37/2010 entries for cefquinome in each jurisdiction.

Lyophilised Dry Powder Fill and Reconstitution Under Nitrogen-Backed Aseptic Lines

For clinics requiring longer shelf life than an aqueous solution permits, cefquinome sulfate is filled as a sterile dry powder for injection, either by freeze-drying a filtered solution or by aseptic dispensing of a micronised dry powder into vials. In lyophilisation, an aqueous solution is filled into depyrogenated Type I glass vials, partially stoppered with bromobutyl closures, and freeze-dried using a shelf programme that cools the product to −40 °C or below, holds for complete solidification, and increases shelf temperature stepwise under high vacuum. The critical process conflict is that cefquinome may degrade in high-moisture collapse zones and may also be sensitive to long exposure at temperatures above 25 °C during secondary drying. Batch records monitor product temperature via thermocouples and chamber pressure via capacitance manometer. Primary drying is operated below the measured collapse temperature, typically in the range of −25 °C to −15 °C for cefquinome formulations; the exact value must be determined by freeze-drying microscopy for each fill volume and vial geometry. Secondary drying ramps to 20–25 °C only after ice sublimation is complete. Residual moisture is controlled to ≤2.0% w/w by Karl Fischer titration. The powder is reconstituted with Water for Injection to a nominal concentration of 25 mg/mL cefquinome base activity before intramuscular use; reconstitution time at 20 °C should be ≤60 s with manual shaking. The terminal product is a sterile powder for injection in single-dose or multi-dose vials. Compliance with Ph. Eur. 5.1.1 and VICH GL18 is mandatory. At relative humidity above 60%, stoppers and containers require pre-drying to prevent caking and hydrolysis during filling.

When Cefquinome Sulfate Is Blended into Feed Premix or Oral Granules

Oral granule and feed premix processing of cefquinome sulfate is not the primary commercial route in most jurisdictions because the β-lactam ring is susceptible to gastric acid hydrolysis, feed-matrix binding, and thermal degradation during pelleting. If a granule batch is required, cefquinome sulfate is dry-blended with lactose monohydrate or microcrystalline cellulose and granulated with an isopropanol-based polyvinylpyrrolidone binder in a top-spray fluidised bed at inlet air temperature not exceeding 40–50 °C. The dried granules are screened through a 1.0 mm sieve and may be film-coated with ethylcellulose to delay dissolution, but coating efficiency must be validated because uncoated β-lactam particles in feed can cross-react with moisture and amines from protein-rich ingredients. Feed premix production must avoid post-pelleting addition to hot meal above 40 °C. Long-term stability at 25 °C/60% RH is limited; manufacturers should conduct forced degradation at 60 °C/75% RH for 14 days to estimate moisture sensitivity. The terminal product, where authorised, is an oral granule or premix for in-feed or top-dressing; however, published data for oral bioavailability of cefquinome in food-producing animals is limited, and oral use may not be supported by approved labels in all markets. Regulatory status must be checked against the national animal drug compendium before adopting this route.

Direct compression of cefquinome sulfate into veterinary tablets is technically constrained not by compressibility but by the API’s sensitivity to moisture, shear heating, and high die-wall pressure. A typical exploratory formulation uses microcrystalline cellulose as filler/dry binder, croscarmellose sodium as disintegrant at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w as lubricant, with cefquinome sulfate load established by the labelled strength. Blending is conducted in a bin blender at 12 rpm for 15–20 min under controlled relative humidity ≤40%. The blend is compressed on a rotary tablet press with precompression force monitored to avoid lamination caused by high elastic recovery. Tablets may be film-coated with hydroxypropyl methylcellulose and titanium dioxide, but aqueous coating at bed temperatures above 40 °C should be reduced or an organic solvent system used to limit β-lactam hydrolysis. Capsule fill uses an automatic dosator capsule machine with fill weight verified by in-line net weight check; hard gelatin capsules are not recommended for high-moisture storage above 60% RH because of cefquinome degradation and capsule cross-linking. Stability of compounded oral tablets and capsules beyond 30 days at 25 °C/60% RH is not established unless confirmed by bracketing studies; published data for this specific configuration is limited. Any terminal product is a compounded or registered tablet/capsule for companion animals, and compliance falls under pharmacy compounding standards or veterinary drug registration dossiers with dissolution testing per Ph. Eur. 2.9.3 or USP <711> as appropriate.

pH-Adjusted Oral Solution and Drench Preparation Limits

Oral solutions of cefquinome sulfate require a buffered aqueous vehicle because the β-lactam ring opening is acid- and base-catalysed, with maximum stability generally reported in the weakly acidic range. A manufacturing approach is to dissolve cefquinome sulfate in purified water at 10–25 mg/mL base activity, add a citrate or acetate buffer to maintain pH 5.0–6.0, and include a preservative if the solution is multi-dose. The solution is filtered through a 0.45 µm or 0.22 µm membrane and filled into amber glass bottles with child-resistant closures. However, aqueous oral cefquinome solution is not a typical authorised commercial presentation in food-producing animals because of low oral bioavailability and the public health risk of increasing cephalosporin resistance selection. Compounding for individual animals must be justified by antimicrobial susceptibility testing. Temperature excursion studies at 40 °C/75% RH and pH drift monitoring after bottle opening are required to define in-use shelf life. If the solution is administered as a drench, viscosity modifiers such as hydroxyethyl cellulose may be added at 0.1–0.5% w/v to improve retention, but this must not exceed the target species’ swallowing capacity. The terminal product is an oral solution or drench for calves, foals, or companion animals under veterinary supervision. Compliance includes VICH GL18 residual solvents, ICH Q3D elemental impurities, and national MRL withholding periods if used in food-producing species.